For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive-compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraine, attention-deficit hyperactivity disorder (ADHD), addiction, dependence, and sleep disorders. They may be prescribed alone or in combination with other medications.
Scope of the Report:
This report focuses on the Anti-depressant Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others)
The worldwide market for Anti-depressant Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- ALKERMES PLC
- ALLERGAN PLC
- BRISTOL MYERS SQUIBB COMPANY
- ELI LILLY AND COMPANY
- GLAXOSMITHKLINE INC.
- H. LUNDBECK A/S
- MERCK INC.
- PFIZER INC.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- TAKEDA PHARMACEUTICAL INC.
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Tricyclic Antidepressants
- Selective Serotonin Reuptake Inhibitors
- Serotonin-Norepinephrine Reuptake Inhibitors
- Monoamine Oxidase Inhibitors
- Serotonin Antagonist
- Reuptake Inhibitors
- Others
Market Segment by Applications, can be divided into
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Others
There are 15 Chapters to deeply display the global Anti-depressant Drugs market.
Chapter 1, to describe Anti-depressant Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anti-depressant Drugs, with sales, revenue, and price of Anti-depressant Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-depressant Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anti-depressant Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anti-depressant Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source